Change of accounting reference date

RNS Number : 5134N

Avacta Group PLC

18 January 2019

 

 18 January 2019

Avacta Group plc

("Avacta", the "Group" or the "Company")

Change of accounting reference date

Avacta Group plc (AIM: AVCT), the developer of Affimer^® biotherapeutics and reagents announces that it has changed its accounting reference date from 31 July to 31 December with immediate effect.

As a result of the change of accounting reference date, the Company's reporting calendar will be as follows:

·     Unaudited interim accounts for the 6 month period ended 31 January 2019 to be published by 30 April 2019;

·     publication of unaudited accounts for the 12 month period ended 31 July 2019 to be published by 31 October 2019; and

·     publication of audited final accounts for the 17 month period ended 31 December 2019 to be published by 31 May 2020.

Thereafter, interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies.

- Ends -

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  [phone] www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern - ECM WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang	Tel:  [phone] www.finncap.com Tel:  [phone] Tel:  [phone] www.wgpartners.co.uk
Turner Pope Investments James Pope Zyme Communications (Trade and Regional Media) Katie Odgaard Yellow Jersey (Financial Media and IR) Sarah Hollins Harriet Jackson	Tel: [phone] [e-mail] Tel: [phone] [e-mail]  Tel: [phone] Tel: [phone] [e-mail]

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer^® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer^® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer^® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer^® reagents through licensing to developers of life sciences research tools and diagnostics.

 

END

 

 

MSCUWVKRKNAAARR